Osimertinib Plus Chemotherapy Improves Progression-Free Survival in EGFR-Mutated NSCLC

Strategic Insights -

A new analysis from the COMPEL trial presents evidence that patients with EGFR-mutated non-small cell lung cancer (NSCLC) who experienced non-central nervous system (CNS) progression on first-line osimertinib can benefit from continuing osimertinib treatment in combination with platinum-based chemotherapy. The study found that median progression-free survival was 8.4 months with osimertinib plus chemotherapy, compared to 4.4 months with placebo plus chemotherapy.

Key Takeaways:

  • The COMPEL study showed that continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC.
  • Median progression-free survival was 8.4 months with osimertinib plus chemotherapy, compared to 4.4 months with placebo plus chemotherapy.
  • Median overall survival was also longer with osimertinib plus chemotherapy (15.9 months) compared to placebo plus chemotherapy (9.8 months).
  • The study supports osimertinib as a backbone treatment strategy in patients with EGFR-mutated advanced NSCLC following progression on targeted therapy.
  • The safety and tolerability profile of the combination therapy was manageable and consistent with the known safety profiles of osimertinib and chemotherapy agents.
  • The findings align with results from the FLAURA2 study, which showed a benefit for first-line osimertinib combined with chemotherapy.

Statistics:

  • 8.4 months: median progression-free survival with osimertinib plus chemotherapy
  • 4.4 months: median progression-free survival with placebo plus chemotherapy
  • 15.9 months: median overall survival with osimertinib plus chemotherapy
  • 9.8 months: median overall survival with placebo plus chemotherapy
  • 0.43: hazard ratio for progression-free survival with osimertinib plus chemotherapy
  • 0.71: hazard ratio for overall survival with osimertinib plus chemotherapy

Sources:

  • International Association for the Study of Lung Cancer
  • Journal of Thoracic Oncology
  • WCLC (World Conference on Lung Cancer)
  • ComPEL trial
  • FLAURA2 study